Last reviewed · How we verify

Aragon Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Aragon Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
ADT (Standard of Care) ADT (Standard of Care) phase 3 Hormonal therapy / Androgen deprivation Androgen receptor / GnRH receptor (depending on specific ADT agent) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Arvinas Androgen Receptor, Inc. · 1 shared drug class
  2. Astellas Pharma · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. City of Hope Medical Center · 1 shared drug class
  5. Pfizer Inc. · 1 shared drug class
  6. Tata Memorial Centre · 1 shared drug class
  7. Triple Hair Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Aragon Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Aragon Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aragon-pharmaceuticals-inc. Accessed 2026-05-17.

Related